A Multicenter, Randomized, Open-label, Positive-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of H001 Capsules in the Prevention of Venous Thromboembolism (VTE) in Subjects Undergoing Total Knee Arthroplasty

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study is a multicenter, randomized, open-label, positive-controlled Phase II clinical study to evaluate the efficacy and safety of H001 capsules in the prevention of venous thromboembolism (VTE) in subjects undergoing Total Knee Arthroplasty.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 74
Healthy Volunteers: f
View:

• Patients scheduled to undergo elective primary unilateral total knee arthroplasty (TKA);

• Aged 18-74 years (inclusive) on the day of signing the informed consent form, regardless of gender;

• Willing and able to voluntarily sign the informed consent form and comply with the study protocol;

• Women of childbearing potential or subjects whose partners are women of childbearing potential must agree to use effective contraception throughout the study period. Acceptable methods include oral, implantable, or injectable hormonal contraceptives; mechanical products (e.g., intrauterine devices, diaphragms, condoms, spermicides); abstinence; or confirmed sterilization (e.g., vasectomy, hysterectomy, bilateral salpingectomy, or bilateral oophorectomy).

Locations
Other Locations
China
Shanghai Sixth People's Hospital
RECRUITING
Shanghai
Contact Information
Primary
Xianlong Zhang, Dr.
Zxl40@vip.sina.com
+86-18930177324
Time Frame
Start Date: 2025-01-20
Estimated Completion Date: 2025-07-30
Participants
Target number of participants: 320
Treatments
Experimental: H001 Capsule 200mg-qd
Experimental: H001 Capsule 300mg-qd
Experimental: H001 Capsule 200mg-bid
Active_comparator: Enoxaparin Sodium Injection
Sponsors
Leads: Livzon Pharmaceutical Group Inc.

This content was sourced from clinicaltrials.gov